ES2052595T3 - Nuevos derivados peptidicos y su aplicacion en especial en terapeutica. - Google Patents

Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.

Info

Publication number
ES2052595T3
ES2052595T3 ES87402845T ES87402845T ES2052595T3 ES 2052595 T3 ES2052595 T3 ES 2052595T3 ES 87402845 T ES87402845 T ES 87402845T ES 87402845 T ES87402845 T ES 87402845T ES 2052595 T3 ES2052595 T3 ES 2052595T3
Authority
ES
Spain
Prior art keywords
therapeutics
orn
application
derivatives
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87402845T
Other languages
English (en)
Inventor
De Rotrou Gerard Arm Marguerie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Cephalon France SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Laboratoire L Lafon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8617507A external-priority patent/FR2608160B1/fr
Priority claimed from FR8708986A external-priority patent/FR2617169B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Laboratoire L Lafon SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2052595T3 publication Critical patent/ES2052595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/75Fibrin; Fibrinogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION TIENE POR OBJETO DERIVADOS PEPTIDICOS DE FORMULA X1-X2-GLY-ASP-X3-X4 EN LA QUE X1 REPRESENTA HIDROGENO, UN GRUPO N-PROTECTOR, UN RESIDUO DE ACIDO AMINADO O UN RESIDUO DE ACIDO AMINADO N-PROTEGIDO. X2 REPRESENTA UN RESIDUO L-ARG O D-ARG, L-ORN O D-ORN, N-AMINO CARBONIL-D-ORN, O L-LYS O D-LYS , X3 REPRESENTA UN RESIDUO L-TRP, D-TRP, L-LEU, D-LEU, L-IIE, L-PHE, D-PHE O UN ENCADENAMIENTO DE 2 O 3 DE ESTOS RESIDUOS, Y X4 REPRESENTA UN GRUPO -OH, -NH2-OR1 CON R1 REPRESENTANDO UN RADICAL ALQUILO EN C1 A C4, NHR2 CON R2 REPRESENTANDO UN RADICAL ALQUILO EN C1 A C4, O UN RESTO DE ACIDO AMINADO. ESTOS DERIVADOS SON UTILES EN TERAPEUTICA EN RAZON DE SU ACTIVIDAD ANTIAGREGANTE.
ES87402845T 1986-12-15 1987-12-14 Nuevos derivados peptidicos y su aplicacion en especial en terapeutica. Expired - Lifetime ES2052595T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8617507A FR2608160B1 (fr) 1986-12-15 1986-12-15 Nouveaux derives peptidiques et leur application notamment en therapeutique
FR8708986A FR2617169B1 (fr) 1987-06-25 1987-06-25 Nouveaux derives peptidiques et leur application notamment en therapeutique

Publications (1)

Publication Number Publication Date
ES2052595T3 true ES2052595T3 (es) 1994-07-16

Family

ID=26225644

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87402845T Expired - Lifetime ES2052595T3 (es) 1986-12-15 1987-12-14 Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.

Country Status (7)

Country Link
US (1) US5100875A (es)
EP (1) EP0275748B1 (es)
JP (1) JP2554346B2 (es)
CA (1) CA1311583C (es)
DE (1) DE3781263T2 (es)
ES (1) ES2052595T3 (es)
GR (1) GR3006288T3 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547936A (en) * 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
EP0394326B1 (en) * 1987-12-10 1996-07-31 La Jolla Cancer Research Foundation Methods for the production of conformationally stabilized cell adhesion peptides
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
CA1324954C (en) * 1988-03-10 1993-12-07 Erkki I. Ruoslahti Inhibition of cell migration with synthetic peptides
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
JPH04504552A (ja) * 1988-11-03 1992-08-13 プライム・テクノロジー・インコーポレーテッド 給紙装置
DE3841753A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5686566A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5807828A (en) * 1989-06-16 1998-09-15 Cor Therapeutics, Inc. Platelet aggregation inhibitors
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
US5395609A (en) * 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
CA2021951A1 (en) * 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
EP0410541A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2021952A1 (en) * 1989-07-28 1991-01-29 Ruth F. Nutt Fibrinogen receptor antagonists
NZ235564A (en) * 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5338723A (en) * 1989-10-13 1994-08-16 Merck & Co., Inc. Fibrinogen receptor antagonists
AU6470590A (en) * 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
WO1991007429A1 (en) * 1989-11-09 1991-05-30 Smithkline Beecham Corporation Anti-aggregatory peptides containing a mercaptan or sulfide moiety
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
GB9007751D0 (en) * 1990-04-05 1990-06-06 Ciba Geigy Ag Novel platelet-aggregation inhibitors
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5648330A (en) * 1990-04-06 1997-07-15 La Jolla Cancer Research Foundation Method and composition for treating vascular graft occlusion
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
DK0527798T3 (da) * 1990-04-06 1997-12-15 Jolla Cancer Res Found Fremgangsmåde og sammensætning til behandling af thrombose
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
WO1992015607A2 (en) * 1991-03-06 1992-09-17 G.D. Searle & Co. Phenyl amidines derivatives useful as platelet aggregation inhibitors
WO1992017492A1 (en) * 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
US5220050A (en) * 1991-05-17 1993-06-15 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA924760B (en) * 1991-06-28 1993-03-31 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5625093A (en) * 1991-10-15 1997-04-29 G. D. Searle & Co. Substituted β-amino acid derivatives useful as platelet aggregation inhibitors
WO1993008818A1 (en) * 1991-11-07 1993-05-13 The University Of Southern California Compositions and methods for preventing adhesion formation
US5441974A (en) * 1991-12-13 1995-08-15 G. D. Searle & Co. Phenyl amidines lactones useful as platelet aggregation inhibitors
US5424334A (en) * 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US5264457A (en) * 1992-02-14 1993-11-23 G. D. Searle & Co. Phenyl amidines sulfonamides useful as platelet aggregation inhibitors
CA2131367A1 (en) * 1992-03-04 1993-09-16 Sandor Bajusz New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
JP3274225B2 (ja) 1992-06-03 2002-04-15 富士写真フイルム株式会社 アミノ酸誘導体及びその用途
WO1994000424A1 (en) * 1992-06-25 1994-01-06 G.D. Searle & Co. Phenyl amidine alkanoic acids and lactones useful as platelet aggregation inhibitors
FR2692899B1 (fr) * 1992-06-30 1994-08-19 Adir Nouveaux dérivés peptidiques actifs dans les processus d'adhésion cellulaire, leur procédé de préparation et les compositions pharmaceutiques qui les renferment.
JPH06192291A (ja) * 1992-09-07 1994-07-12 Nippon Steel Corp 新規ペプチドとそれを用いた血小板凝集抑制剤及び血液凝固抑制剤
US6380163B1 (en) * 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
US5409939A (en) * 1993-02-12 1995-04-25 G. D. Searle & Co. Phenyl amidine thio derivatives useful as platelet aggregation inhibitors
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
US5612355A (en) * 1993-06-23 1997-03-18 G. D. Searle & Co. Phenyl amidine lactones useful as platelet aggregation inhibitors
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6387880B1 (en) 1994-10-24 2002-05-14 G.D. Searle & Co. Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts
US5677276A (en) * 1994-12-23 1997-10-14 La Jolla Cancer Research Foundation Immobilization of peptides to hyaluronate
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
KR100512671B1 (ko) * 1996-11-27 2005-09-07 아벤티스 파마슈티칼스 인크. 항 Xa 활성을 지닌 화합물 및 혈소판 응집 길항제 화합물을포함하는 약제학적 조성물
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
US6037365A (en) * 1998-09-25 2000-03-14 G.D. Searle & Co. Aminobenzamidinosuccinyl lactone derivatives useful as inhibitors of platelet aggregation
JP2007534612A (ja) * 2003-04-22 2007-11-29 アバニール・ファーマシューティカルズ 高コレステロール血症の治療のためのコレステロール逆輸送メディエータ
US20050159362A1 (en) * 2003-04-22 2005-07-21 Sircar Jagadish C. Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
CA2804926C (en) 2010-07-09 2019-01-08 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
WO2015103643A2 (en) * 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
CN112430254B (zh) * 2020-11-25 2021-10-26 广东海洋大学 一种抗凝血活性肽衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
DE3421614A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von pentapeptiden mit wirkung auf das immunsystem und zwischenprodukte dieses verfahrens
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
FR2608160B1 (fr) * 1986-12-15 1989-03-31 Inst Nat Sante Rech Med Nouveaux derives peptidiques et leur application notamment en therapeutique
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives

Also Published As

Publication number Publication date
JPS63215696A (ja) 1988-09-08
CA1311583C (en) 1992-12-15
DE3781263T2 (de) 1993-04-08
US5100875A (en) 1992-03-31
DE3781263D1 (de) 1992-09-24
EP0275748B1 (fr) 1992-08-19
EP0275748A1 (fr) 1988-07-27
GR3006288T3 (es) 1993-06-21
JP2554346B2 (ja) 1996-11-13

Similar Documents

Publication Publication Date Title
ES2052595T3 (es) Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.
AR053946A2 (es) Variante de alfa-amilasa de bacillus stearothermophilus original
ATE532533T1 (de) Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen
ES2072779T3 (es) Derivados aminoacidos anfoteros.
PE123699A1 (es) Nitrilos de dipeptido
ATE428785T1 (de) Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
CO4700527A1 (es) Nuevos peptidos, su preparacion y su uso
DE3761286D1 (de) Haarkosmetische mittel.
ATE201696T1 (de) Zyklische peptidanaloga von somatostatin
DK164409C (da) Lhrh-antagonister og ikke-toksiske salte deraf samt farmaceutisk middel indeholdende disse
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
ES553792A0 (es) Un procedimiento para la prepacion de un peptido que tiene prolilamida c-terminal.
DE69019192D1 (de) Electrolyse-Vorrichtung für Chlor-Alkali-Electrolyse und Anode.
MY106287A (en) Acid addition salts of amidated taurine or glycine, their preparation and use
TR199802376T1 (xx) Aspergıllus Phoenıces'den Oksalat Dekarboksilaz Kodlayan Gen.
BR9510372A (pt) Processo de preparação de alfa ómega-aminonitrilas
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
MX169334B (es) Preparacion de liberacion sostenida
HUP0000882A2 (hu) NMDA (N-metil-D-aszpartát) antagonista hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyszerkészítmények
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
DK0977871T3 (da) Neurotrypsin
ZA852495B (en) Anticonvulsant agents
BR9714376A (pt) Antagonistas de somatostatina
DK527187A (da) Gonadoliberin-analoge, fremgangsmaade til deres fremstilling samt deres anvendelse som laegemidler

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 275748

Country of ref document: ES